Table 3.
Summary of non-randomized clinical trials evaluating the antiproliferative effect of somatostatin analogs n (%)
| Analog | Author | n | CR/PR | SD | PD |
| Patients with documented tumor progression | |||||
| Lanreotide | Faiss et al[62], 2003 | 22 | 1 (4) | 7 (32) | 14 (64) |
| Lanreotide | Aparicio et al[63], 2001 | 35 | 1 (3) | 20 (57) | 14 (40) |
| Octreotide | Arnold et al[64], 1993 | 52 | 0 (0) | 19 (36) | 33 (63) |
| Octreotide | Saltz et al[58], 1993 | 34 | 0 (0) | 17 (50) | 17 (50) |
| Octreotide | di Bartolomeo et al[19], 1996 | 58 | 2 (3) | 27 (46) | 29 (50) |
| 201 | 4 (1) | 90 (45) | 107 (53) | ||
| Patients without documented tumor progression | |||||
| Lanreotide | Wymenga et al[60], 1999 | 31 | 2 (6) | 25 (80) | 4 (13) |
| Lanreotide | Ducreux et al[59], 2000 | 39 | 2 (5) | 21 (54) | 16 (41) |
| Lanreotide | Eriksson et al[65], 1997 | 19 | 1 (5) | 12 (63) | 6 (32) |
| Lanreotide | Tomasetti et al[66], 1998 | 18 | 0 (0) | 14 (77) | 4 (22) |
| Octreotide | Tomasetti et al[67], 2000 | 16 | 0 (0) | 14 (87) | 2 (12) |
| Octreotide | Ricci et al[68], 2000 | 15 | 1 (6) | 6 (40) | 8 (53) |
| 138 | 6 (4) | 92 (67) | 40 (29) | ||
CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.